Everpar Advisors LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,884 shares of the medical research company’s stock, valued at approximately $918,000.
A number of other hedge funds have also made changes to their positions in CRL. Meritage Group LP purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $173,174,000. Rhenman & Partners Asset Management AB acquired a new position in Charles River Laboratories International in the 3rd quarter worth $48,603,000. Montrusco Bolton Investments Inc. lifted its holdings in Charles River Laboratories International by 35.8% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 855,387 shares of the medical research company’s stock worth $164,058,000 after buying an additional 225,562 shares in the last quarter. Armistice Capital LLC acquired a new position in Charles River Laboratories International in the 3rd quarter worth $30,573,000. Finally, abrdn plc lifted its holdings in Charles River Laboratories International by 872.0% in the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock worth $28,795,000 after buying an additional 109,275 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.
Insider Transactions at Charles River Laboratories International
In related news, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at approximately $3,437,635. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,932 shares of company stock worth $3,693,663. Insiders own 1.30% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Research Report on Charles River Laboratories International
Charles River Laboratories International Stock Performance
CRL stock traded down $0.97 during midday trading on Wednesday, reaching $235.34. The company had a trading volume of 610,304 shares, compared to its average volume of 543,878. The firm has a market capitalization of $12.12 billion, a PE ratio of 25.66, a P/E/G ratio of 1.83 and a beta of 1.44. The stock has a 50 day moving average price of $251.61 and a 200 day moving average price of $225.17. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same quarter in the previous year, the firm posted $2.98 EPS. The business’s revenue for the quarter was down 7.9% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- What Does a Stock Split Mean?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Generac Powers Ahead on the Electrification Mega-Trend
- Pros And Cons Of Monthly Dividend Stocks
- PulteGroup Wins and Wins More on Interest Rate Cuts
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.